Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Crispr Therapeutics Ag (CRSP)

Crispr Therapeutics Ag (CRSP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,501,435
  • Shares Outstanding, K 70,172
  • Annual Sales, $ 289,590 K
  • Annual Income, $ 66,860 K
  • 60-Month Beta 2.31
  • Price/Sales 21.85
  • Price/Cash Flow 69.52
  • Price/Book 7.11
Trade CRSP with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -1.17
  • Number of Estimates 9
  • High Estimate -0.87
  • Low Estimate -1.29
  • Prior Year 2.40
  • Growth Rate Est. (year over year) -148.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
79.31 +16.82%
on 10/02/20
111.90 -17.20%
on 10/16/20
+7.96 (+9.40%)
since 09/23/20
3-Month
76.71 +20.78%
on 09/04/20
111.90 -17.20%
on 10/16/20
+1.85 (+2.04%)
since 07/23/20
52-Week
32.30 +186.84%
on 03/16/20
111.90 -17.20%
on 10/16/20
+53.42 (+136.17%)
since 10/23/19

Most Recent Stories

More News
CRISPR (CRSP) Falls Despite Positive Data on Lymphoma Study

CRISPR Therapeutics (CRSP) reports top-line data from a phase I study, currently evaluating its pipeline candidate CTX110 for CD19+ B-cell malignancies. Shares down.

VRTX : 211.58 (+0.71%)
CRSP : 92.65 (+2.76%)
ALNA : 1.3900 (-2.11%)
ETON : 7.64 (-3.78%)
Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates

The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.

BIIB : 265.00 (-0.67%)
REGN : 579.81 (+0.71%)
GILD : 60.79 (+0.20%)
VRTX : 211.58 (+0.71%)
BSTC : 88.16 (+0.05%)
CRSP : 92.65 (+2.76%)
CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110(TM) in Relapsed or Refractory CD19+ B-cell Malignancies

-50% (2/4) complete response (CR) rate at three months in the Dose Level 3 (DL3) cohort; both responders remain in CR-

CRSP : 92.65 (+2.76%)
3 Top Genomics Stocks to Buy for 2021 and Beyond

Genomics is a medical industry predicted to significantly grow over the next 7 years. To get involved, consider adding Regeneron Pharmaceuticals (REGN), CRISPR Therapeutics (CRSP) and Invitae Corporation...

REGN : 579.81 (+0.71%)
CRSP : 92.65 (+2.76%)
NVTA : 45.26 (-1.63%)
Why You Should Invest in Genomics ETFs

Genomics ETFs have surged of late; here's why

REGN : 579.81 (+0.71%)
GILD : 60.79 (+0.20%)
NVTA : 45.26 (-1.63%)
CRSP : 92.65 (+2.76%)
ARKG : 70.11 (+1.18%)
GNOM : 18.88 (-0.36%)
IDNA : 39.66 (+0.03%)
Vertex to End Phase II Study on AAT Deficiency Candidate

Vertex (VRTX) to discontinue phase II study on VX-814 based on the liver enzyme elevations observed and the determination that it would be difficult to safely achieve targeted exposure levels.

VRTX : 211.58 (+0.71%)
EBS : 96.11 (-1.58%)
HZNP : 77.44 (+1.81%)
CRSP : 92.65 (+2.76%)
Booming Gene Editing Market to Pep Up These 5 Biotech Stocks

Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.

TMO : 480.17 (-0.38%)
VRTX : 211.58 (+0.71%)
EBS : 96.11 (-1.58%)
EDIT : 32.76 (+1.57%)
CLLS : 19.41 (+8.74%)
NTLA : 24.88 (+0.28%)
CRSP : 92.65 (+2.76%)
NASDAQ Jumps 4%+ This Week, While S&P, Dow Rise Over 3%

NASDAQ Jumps 4%+ This Week, While S&P, Dow Rise Over 3%

AGYS : 26.72 (+2.18%)
NTLA : 24.88 (+0.28%)
EDIT : 32.76 (+1.57%)
CRSP : 92.65 (+2.76%)
SGMO : 10.84 (+1.78%)
HEAR : 19.30 (+2.88%)
JPM : 103.81 (+0.90%)
C : 43.95 (unch)
BAC : 24.90 (+0.12%)
GS : 205.04 (-0.18%)
MS : 51.87 (+0.19%)
The Innovative Future Of ETFs

The Innovative Future Of ETFs

TSLA : 420.63 (-1.21%)
SQ : 176.77 (+0.48%)
ROKU : 223.96 (+0.72%)
PRLB : 137.25 (+0.38%)
NVTA : 45.26 (-1.63%)
CRSP : 92.65 (+2.76%)
ARKK : 99.18 (+0.61%)
Big October Winners: CRISPR, Alteryx, NVIDIA, Quidel

Two women will share the Nobel prize for a gene editing technology that will change the world.

NVDA : 543.61 (+1.72%)
QDEL : 248.21 (+1.01%)
EDIT : 32.76 (+1.57%)
TTD : 619.91 (+2.14%)
NTLA : 24.88 (+0.28%)
CRSP : 92.65 (+2.76%)
AYX : 138.82 (+1.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

See More

Key Turning Points

2nd Resistance Point 96.38
1st Resistance Point 94.51
Last Price 92.65
1st Support Level 89.15
2nd Support Level 85.65

See More

52-Week High 111.90
Last Price 92.65
Fibonacci 61.8% 81.49
Fibonacci 50% 72.10
Fibonacci 38.2% 62.71
52-Week Low 32.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar